The immunopeptidomic landscape of ovarian carcinomas [Immunology and Inflammation]
Immunotherapies, particularly checkpoint inhibitors, have set off a revolution in cancer therapy by releasing the power of the immune system. However, only little is known about the antigens that are essentially presented on cancer cells, capable of exposing them to immune cells. Large-scale HLA ligandome analysis has enabled us to...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Heiko Schuster, Janet K. Peper, Hans–Christian Bosmuller, Kevin Rohle, Linus Backert, Tatȷana Bilich, Britta Ney, Markus W. Loffler, Daniel J. Kowalewski, Nico Trautwein, Armin Rabsteyn, Tobias Engler, Sabine Braun, Sebastian P. Haen, Juliane Tags: PNAS Plus Source Type: research
More News: Academies | Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Immunotherapy | Ovarian Cancer | Ovaries